Theralizumab

Drug Profile

Theralizumab

Alternative Names: TAB-08; TABO8

Latest Information Update: 02 Jan 2017

Price : $50

At a glance

  • Originator TheraMAB
  • Class Antineoplastics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Systemic lupus erythematosus
  • Phase I/II Plaque psoriasis
  • No development reported Chronic lymphocytic leukaemia; Rheumatoid arthritis

Most Recent Events

  • 26 Dec 2016 TheraMAB plans a phase Ib trial for Solid tumours (Metastatic disease, Inoperable/Unresectable, Late-stage disease) in Russia (NCT03006029)
  • 01 Apr 2016 Phase-I/II clinical trials in Plaque psoriasis in Russia (IV) (NCT02796053)
  • 17 Mar 2016 TheraMab plans a phase II trial for Systemic lupus erythematosus in Russia (IV) (NCT02711813)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top